Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands

M. A. Piena, M. Heisen, L. W. Wormhoudt, J. van Wingerden, S. T. F. M. Frequin, B. M. J. Uitdehaag
  • Journal of Medical Economics, July 2018, Taylor & Francis
  • DOI: 10.1080/13696998.2018.1489255

The authors haven't yet claimed this publication.

Read Publication

In partnership with: